VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

The company announced an aggregate cash dividend of an estimated $16.5 million, equivalent to an estimated $0.38 per share. With no additional context on changes vs. prior periods or payout increases/decreases, the announcement appears modestly positive and unlikely to be broadly market-moving.

Analysis

The company announced an aggregate cash dividend of an estimated $16.5 million, equivalent to an estimated $0.38 per share. With no additional context on changes vs. prior periods or payout increases/decreases, the announcement appears modestly positive and unlikely to be broadly market-moving.